Indication Expansion Approved by Ministry of Food and Drug Safety

Korea GSK announced on July 3 that its respiratory syncytial virus (RSV) vaccine, Arex-B, has received approval from the Ministry of Food and Drug Safety to expand its indication to include high-risk adults aged 18 to 49.


Korea GSK Arexvi Product Image. Korea GSK

Korea GSK Arexvi Product Image. Korea GSK

View original image

With this approval, the eligible population for Arex-B has been extended from adults aged 60 and above and high-risk individuals aged 50 to 59, to now include high-risk adults aged 18 to 49. As a result, the vaccine can now be used across all adult age groups at high risk of RSV infection.


The expanded indication targets adults at high risk of developing lower respiratory tract disease due to RSV, such as those with chronic respiratory disease, chronic cardiovascular disease, diabetes with complications, end-stage renal disease, or moderate to severe immunosuppression.


This expanded indication is based on results from a global phase 3b clinical trial conducted in adults aged 18 to 49 with chronic conditions. In the trial, Arex-B demonstrated non-inferior immunogenicity compared to adults aged 60 and over, and showed a similar safety profile.


In previous clinical trials, Arex-B demonstrated an 82.6% efficacy rate in preventing RSV lower respiratory tract disease among adults aged 60 and over. For those in this age group with at least one comorbid condition, the efficacy rate was 94.6%.


RSV is a virus that causes acute respiratory infections and poses a high risk of severe illness in the elderly and those with chronic diseases. Studies have shown that RSV infection significantly increases the risk of hospitalization among patients with asthma, chronic obstructive pulmonary disease (COPD), heart failure, and diabetes. Hospitalized patients are also known to be at increased risk of worsening underlying conditions such as COPD and heart failure.


Currently, there are no specific treatments for adult RSV infection aside from supportive care, making vaccination particularly important. According to the Korean Society of Infectious Diseases' adult immunization guidelines, vaccination is recommended for adults aged 75 and older and for high-risk RSV groups.



Hyunji Kwon, Executive Director and Head of Vaccines at Korea GSK, stated, "This expanded indication establishes a preventive foundation that spans all adult age groups at high risk for RSV infection. We will continue to raise awareness of the importance of RSV prevention and collaborate with health authorities and medical professionals to ensure that high-risk groups can receive timely vaccination."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing